SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for SenesTech, Inc. (SNES) (CIK 0001680378) (SNES) — Feb 11, 2020

SenesTech, Inc. (SNES) (CIK 0001680378)
Date: Feb. 11, 2020 · CIK: 0001680378 · Accession: 0000000000-20-001297

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-236302

Date
February 11, 2020
Author
Tom Chesterman
Form
UPLOAD
Company
SenesTech, Inc. (SNES) (CIK 0001680378)

Letter

February 11, 2020 Tom Chesterman Chief Financial Officer SenesTech, Inc. 23460 N 19th Ave., Suite 110 Phoenix, AZ 85027 Re:SenesTech, Inc. Registration Statement on Form S-1 Filed February 7, 2020 File No. 333-236302 Dear Mr. Chesterman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Courtney Lindsay at (202) 551-7237 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Kara Tatman

Show Raw Text
February 11, 2020
Tom Chesterman
Chief Financial Officer
SenesTech, Inc.
23460 N 19th Ave., Suite 110
Phoenix, AZ 85027
Re:SenesTech, Inc.
Registration Statement on Form S-1
Filed February 7, 2020
File No. 333-236302
Dear Mr. Chesterman:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Courtney Lindsay at (202) 551-7237 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Kara Tatman